David Budd, CEO of genedrive, a molecular diagnostics company, says adoption of point of care genetic testing in emergency settings will help save lives and money. However, innovators need to work to persuade healthcare funders to adopt these life-saving technologies.
Key insights:
- Pharmacogenetic testing can enable opportunities for more personalised medical responses such as rapid point-of-care-testing (POCT) which can be used by clinicians at the patient’s bedside.
- POCT can determine patient responses to medical treatments as a result of their genetic code, offering a test result with an hour - proving useful in emergency situations.
- genedrive are supporting Trusts by providing health economic modelling tools to help them assess how many patients can avoid adverse events and the associated costs. This decentralised approach is valuable at a time of cost pressures in the NHS.
Pharmacogenetic testing is an established and advancing health technology that tracks how a person’s genes affect their body's response to medical treatments.